EGFR and non-small cell lung carcinoma: The importance of testing NSCLC for EGFR mutations at earlier stages of management is further reinforced by the recent results of the ADAURA trial which enrolled patients with NSCLC harboring EGFR exon 19 deletions or exon 21 L858R mutations (13).